H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act
Access and reimbursement of Part B Drugs in Medicare.
Continued expansion of Telehealth services including in H.R. 3857/S.3967 - Expanded Telehealth Access Act and Telehealth Modernization Act.
H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
H.R.4822 - Health Care Price Transparency Act of 2023
H.R. 3284, the Providers and Payers COMPETE Act.
Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458)
H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Duration: January 1, 2011
to
present
General Issues: Medicare/Medicaid , Health Issues , Veterans , Small Business
Spending: about $4,390,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 22.
Original Filing: 301575927.xml
Lobbying Issues
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act
Access and reimbursement of Part B Drugs in Medicare.
Continued expansion of Telehealth services including in H.R. 3857/S.3967 - Expanded Telehealth Access Act and Telehealth Modernization Act.
H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
H.R.4822 - Health Care Price Transparency Act of 2023
H.R. 3284, the Providers and Payers COMPETE Act.
Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458)
H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 20.
Original Filing: 301534000.xml
Lobbying Issues
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act
Access and reimbursement of Part B Drugs in Medicare.
Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act.
H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
H.R.4822 - Health Care Price Transparency Act of 2023
H.R. 3284, the Providers and Payers COMPETE Act.
Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458)
H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
H.R.2880 - Protecting Patients Against PBM Abuses Act
Continued expansion of Telehealth services including in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516567.xml
Lobbying Issues
Access and reimbursement of Part B Drugs in Medicare.
Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act.
H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Support for site neutrality policies.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
H.R. 3284, the Providers and Payers COMPETE Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act.
S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2023.
Original Filing: 301490346.xml
Lobbying Issues
Access and reimbursement of Part B Drugs in Medicare.
Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act.
H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Support for site neutrality policies.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
H.R. 3284, the Providers and Payers COMPETE Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2023.
Original Filing: 301466835.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act.
Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Support for site neutrality policies.
Support for Sec. 4113 - Advancing Telehealth Beyond COVID-19 included in H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to implementation and enforcement of the CY 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule with Comment Period CMS 1772-FC.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438476.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Support for site neutrality policies.
Issues related to payments cuts to the Medicare Physician Fee Schedule including in H.R.8800 - Supporting Medicare Providers Act of 2022 and Sec.4112 of H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
Support for Sec. 4113 - Advancing Telehealth Beyond COVID-19 included in H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Support inclusion of Sec. 102 - Department of Veterans Affairs treatment and research of prostate
cancer in Title I Subtitle A of H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415232.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Support for site neutrality policies.
Issues related to physician payments included in H.R. 8800 - Supporting Medicare Providers Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2022.
Original Filing: 301390295.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill.
Support for site neutrality policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2022.
Original Filing: 301365260.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Support for site neutrality policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 20, 2022.
Original Filing: 301335996.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Issues related to physician payment cuts addressed in S. 610 - Protecting Medicare and American Farmers from Sequester Cuts Act and H.R. 6143 - Supporting Health Care Providers During the COVID-19 Pandemic Act.
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311602.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2021.
Original Filing: 301284504.xml
Lobbying Issues
Access and reimbursement of Part B drugs in Medicare.
Extension to Medicare sequester delay in S. 748 - A Bill to Provide for an Extension of the Temporary Suspension of Medicare Sequestration During the COVID-19 Public Health Emergency, H.R. 1868 - To Prevent Across-The-Board Direct Spending Cuts, and For Other Purposes, H.R. 315 - Medicare Sequester COVID Moratorium Act and H.R.1999 - To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services including in H.R. 2168 - Expanded Telehealth Access Act and S. 368/H.R. 1332 - Telehealth Modernization Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2021.
Original Filing: 301264351.xml
Lobbying Issues
Extension to Medicare sequester delay in S. 748 - A Bill to Provide for an Extension of the Temporary Suspension of Medicare Sequestration During the COVID-19 Public Health Emergency, H.R. 1868 - To Prevent Across-The-Board Direct Spending Cuts, and For Other Purposes, H.R. 315 - Medicare Sequester COVID Moratorium Act and H.R.1999 - To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Continued expansion of Telehealth services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234779.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019.
Support site neutrality proposals.
Reform to Stark Law and Anti-Kickback statute Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694).
Implementation of Public Law 116-136.
Most Favored Nation (MFN) Model, (CMS-5528-IFC).
Extension to Medicare sequester delay in Division N Sec. 102 of H.R. 133 - Consolidated Appropriations Act, 2020 and H.R. 8840 - Medicare Sequester COVID Moratorium Act.
Delay of implementation of the Radiation Oncology Model in Division CC Sec. 133 of H.R. 133.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6092, the Veteran's Prostate Cancer Treatment and Research Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 14, 2020.
Original Filing: 301209649.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019.
Support site neutrality proposals.
Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694).
Implementation of Public Law 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6092, the Veteran's Prostate Cancer Treatment and Research Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 14, 2020.
Original Filing: 301187531.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019.
Opposition to step therapy requirement in Medicare Advantage.
Support site neutrality proposals.
Oppose H.R. 2143.
Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694).
Implementation of the Public Health and Social Services Emergency Fund in H.R. 748.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019. S. 3559/H.R. 6365, the Immediate Relief for Rural Facilities and Providers Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Paycheck Protection Program and H.R. 7010/ S. 3805, the Paycheck Protection Flexibility Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 19, 2020.
Original Filing: 301172511.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019.
Opposition to step therapy requirement in Medicare Advantage.
OPPS/ ASC Payment Rule, (85 FR 224).
Lobbied against the International Pricing Index model (83 FR 54546).
Support site neutrality proposals.
Oppose H.R. 2143.
Proposed Radiation Oncology (RO) Model, 84 FR 34478.
Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694).
S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
The Public Health and Social Services Emergency Fund in H.R. 748, the CARES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019. S. 3559/H.R. 6365, the Immediate Relief for Rural Facilities and Providers Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Paycheck Protection Program in H.R. 748, the CARES Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 17, 2020.
Original Filing: 301108736.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019.
Opposition to step therapy requirement in Medicare Advantage.
OPPS/ ASC Proposed Payment Rule, (84 FR 39398).
Lobbied against the International Pricing Index model (83 FR 54546).
Support site neutrality proposals.
Oppose H.R. 2143.
Proposed Radiation Oncology (RO) Model, 84 FR 34478.
Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694).
S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 21, 2019.
Original Filing: 301073413.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. Proposed Radiation Oncology (RO) Model, 84 FR 34478. S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 16, 2019.
Original Filing: 301046751.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 22, 2019.
Original Filing: 301033588.xml
Lobbying Issues
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for reforming the United States Preventive Services Task Force.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 22, 2019.
Original Filing: 301017201.xml
Lobbying Issues
Support for H.R. 4206 / S. 2051 - Medicare Care Coordination Improvement Act of 2017. Opposition to H.R. 2066 - PIMA of 2017. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 - USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 19, 2018.
Original Filing: 300991271.xml
Lobbying Issues
Support for H.R. 4206 / S. 2051 - Medicare Care Coordination Improvement Act of 2017. Opposition to H.R. 2066 - PIMA of 2017. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, 83 Fed. Reg. 37046.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 - USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2018.
Original Filing: 300974634.xml
Lobbying Issues
Support for H.R. 4206 / S. 2051 - Medicare Care Coordination Improvement Act of 2017. Opposition to H.R. 2066 - PIMA of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 - USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2018.
Original Filing: 300955179.xml
Lobbying Issues
Support for H.R. 4206 / S. 2051 - Medicare Care Coordination Improvement Act of 2017. Opposition to H.R. 2066 - PIMA of 2017
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 - USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929444.xml
Lobbying Issues
Support for H.R. 4206 / S. 2051 - Medicare Care Coordination Improvement Act of 2017. Opposition to H.R. 2066 - PIMA of 2017
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910245.xml
Lobbying Issues
Opposition to H.R. 2066 - PIMA of 2017. Support for Stark self referral reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2017.
Original Filing: 300894418.xml
Lobbying Issues
Opposition to H.R. 2066 - PIMA of 2017. Support for Stark self referral reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2017.
Original Filing: 300876656.xml
Lobbying Issues
Opposition to H.R. 2066 - PIMA of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for H.R. 539 USPSTF Transparency and Accountability Act of 2017.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 19, 2017.
Original Filing: 300851652.xml
Lobbying Issues
Opposition to proposed Part B demo (81 FR 13229). MACRA Implementation (81 FR 28161). Support for H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.Opposition to H.R.5088 - PIMA of 2016.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015. S.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 19, 2016.
Original Filing: 300833964.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Opposition to proposed Part B demo (81 FR 13229). MACRA Implementation (81 FR 28161). Support for H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 19, 2016.
Original Filing: 300813349.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Opposition to proposed Part B demo (81 FR 13229). MACRA Implementation (81 FR 28161).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
THE MCMANUS GROUP amended a lobbying report for representation of Large Urology Group Practice Association in Q12016 on June 30, 2016.
Original Filing: 300806328.xml
Lobbying Issues
Preserve the in-office ancillary services exception. S.2425, Patient Access and Medicare Protection Act.Opposition to proposed Part B demo (81 FR 13229)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2016.
Original Filing: 300800578.xml
Lobbying Issues
Preserve the in-office ancillary services exception. S.2425, Patient Access and Medicare Protection Act.Opposition to proposed Part B demo (81 FR 13229)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 20, 2016.
Original Filing: 300783249.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Education and advocacy regarding proposed radiation cuts in CY 2016 Proposed Rule for Medicare Physician Fee Schedule. S.2425, Patient Access and Medicare Protection Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763692.xml
Lobbying Issues
Preserve the in-office ancillary services exception.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015. Education and advocacy regarding proposed radiation cuts in CY 2016 Proposed Rule for Medicare Physician Fee Schedule.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
THE MCMANUS GROUP amended a lobbying report for representation of Large Urology Group Practice Association in Q32015 on Oct. 20, 2015.
Original Filing: 300763737.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Education and advocacy regarding proposed radiation cuts in CY 2016 Proposed Rule for Medicare Physician Fee Schedule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 20, 2015.
Original Filing: 300745004.xml
Lobbying Issues
Preserve the in-office ancillary services exception.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1151 - USPSTF Transparency and Accountability Act of 2015
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 20, 2015.
Original Filing: 300722410.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Support H.R.2 - Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704920.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Greater transparency in CMS rulemaking. Opposition to radiation therapy cuts.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on Oct. 20, 2014.
Original Filing: 300687206.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Greater transparency in CMS rulemaking.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on July 17, 2014.
Original Filing: 300659727.xml
Lobbying Issues
Preserve the in-office ancillary services exception. Payment reform issues in HR 4015 and S 2000, "SGR Repeal and Medicare Provider Payment Mdernization Act of 2014"
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $90,000. The report was filed on April 21, 2014.
Original Filing: 300647993.xml
Lobbying Issues
Prevent changes to in office ancillary services exception. Payment reform issues in H.R.4302 "Protecting Access to Medicare Act of 2014," HR 4015 "SGR Repeal and Medicare Provider Payment Modernization Act of 2014," S.2110 "Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014," S.1871 & H.R. 2810 "SGR Repeal and Medicare Beneficiary Access Act of 2013," and S. 2000 "SGR Repeal and Medicare Provider Payment Modernization Act of 2014."
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Jan. 21, 2014.
Original Filing: 300625294.xml
Lobbying Issues
Physician in-office ancillary services exception issues. HR 2914, "Promoting Integrity in Medicare Act of 2013." Physician reimbursement under the Sustainable Growth Rate. Paymet reform issues in S. 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013" & H.R. 2810 "Medicare Patient Access and Quality Improvement Act of 2013."
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300606930.xml
Lobbying Issues
Physician in-office ancillary services exception issues.
HR 2914, "Promoting Integrity in Medicare Act of 2013."
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300583867.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300561325.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300541697.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Physician payment rule issues regarding radiation therapy and CMS rule RIN 0938AR11 regarding physician fee schedule.
Section 601 of HR 8, "American Taxpayer Relief Act of 2012."
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test.
Promotion of greater transparency of USPSTF.
Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512339.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Physician payment rule issues regarding radiation therapy.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test.
Promotion of greater transparency of USPSTF.
Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300494640.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) recommendation regarding the prostate-specific antigen test.
Promotion of greater transparency of USPSTF.
Support for H.R. 5998, "USPSTF Transparency and Accountability Act of 2012."
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on April 20, 2012.
Original Filing: 300471689.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Support for S 2243, "Medicare Better Health Rewards Program Act of 2012"
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to the U.S. Preventative Services Task Force (USPSTF) draft recommendation regarding the prostate-specific antigen test.
Promotion of greater transparency of USPSTF.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Jan. 19, 2012.
Original Filing: 300444868.xml
Lobbying Issues
Physician self-referral issues.
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to the U.S. Preventative Services Task Force draft recommendation regarding the prostate-specific antigen test.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $60,000. The report was filed on Oct. 19, 2011.
Original Filing: 300420217.xml
Lobbying Issues
Physician self-referral issues.
Support for H.R.452 "Medicare Decisions Accountability Act of 2011" and S.668 "Health Care Bureaucrats Elimination Act."
Physician reimbursement under the Sustainable Growth Rate.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $50,000. The report was filed on July 15, 2011.
Original Filing: 300391024.xml
Lobbying Issues
Physician self-referral issues.
Opposition to imaging payment cuts in the US-Korea Free Trade Agreement.
Support for H.R.452 Medicare Decisions Accountability Act of 2011 and S.668 Health Care Bureaucrats Elimination Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, THE MCMANUS GROUP lobbied for Large Urology Group Practice Association , earning $50,000. The report was filed on April 18, 2011.
Original Filing: 300366633.xml
Lobbying Issues
Physician self-referral issues.
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...